Back to News
Nov 18, 2025 12:00 PM

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.

Olema Pharmaceuticals' stock surged over 200% in reaction to Roche Holdings AG's (OTC:RHHBY) phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stage breast cancer.

The trial evaluated giredestrant as an adjuvant (refers to treatments given after the main treatment) endocrine treatment for oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative.

The study met its primary endpoint at a pre-planned interim analysis, showing a statistically significant and clinically meaningful improvement in invasive disease-free survival with giredestrant versus standard-of-care endocrine therapy.

Also Read: Roche Targets Top Spot In Weight Loss Drug Market

Roche's Trial Redefines Breast Cancer Treatment

Roche on Tuesday said that lidERA is the first phase 3 trial of a selective oestrogen ...